Código QR (código de barras bidimensional)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

Abstract Background Approximately 30–70% of patients who have undergone allogeneic (allo) hematopoietic stem cell transplantation (HSCT) eventually experience chronic graft-versus-host disease (cGVHD). Patients who develop steroid-refractory (SR)-cGVHD are the most severely impacted due to significa...

Fuld beskrivelse

Na minha lista:
Principais autores: Jian Chun Matthew Ong, Hein Than, Sandeep Tripathi, Christina Gkitzia, Xiaojun Wang
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2023-05-01
Serier:Cost Effectiveness and Resource Allocation
Fag:
Cost
cGVHD
Allogeneic
Transplant
Ruxolitinib
QALY
Online adgang:https://doi.org/10.1186/s12962-023-00444-w
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker